IVI and Zambia
Ongoing Collaboration
Global Burden of Human Papillomavirus (GLOBE HPV)
IVI and its partners are conducting GLOBE HPV, a global disease burden study to generate robust primary data on the prevalence and impact of human papillomavirus (HPV) among girls and women in low- and middle-income countries across South Asia and sub-Saharan Africa. This five-year study aims to estimate the prevalence of high-risk HPV genotype infections among representative samples of girls and women aged 9 to 50 years, as well as specific subpopulations, to better understand the incidence of persistent HPV infection.
The study spans three countries in Asia: Bangladesh, Nepal, and Pakistan; and five in sub-Saharan Africa: the Democratic Republic of the Congo, Ghana, Sierra Leone, Tanzania, and Zambia. In Zambia, IVI works alongside Zambart.
The study consists of cross-sectional surveys in general populations, longitudinal studies, special population studies, and qualitative research. In addition to assessing HPV prevalence, researchers will collect data on girls’ and women’s knowledge, attitudes, and beliefs regarding HPV interventions, perceptions of gender norms and stigma, and gender-related factors that may influence HPV burden or create barriers to accessing and utilizing HPV prevention, screening, and treatment services.
In 2024, large-scale cross-sectoral surveys and longitudinal cohort studies were launched across all eight countries. The findings from this study will provide a more accurate understanding of the HPV disease burden and the obstacles to effective interventions at both national and global levels. These insights will help inform policymakers and health program designers, guiding research and development efforts toward interventions with the greatest potential public health impact.
GLOBE HPV is done in collaboration with the London School of Hygiene and Tropical Medicine, the Karolinska Institutet, and the U.S. CDC and is made possible by $17.2 million USD in funding from the Gates Foundation and the Government of Sweden.
Regional Antimicrobial Resistance Data Analysis for Advocacy, Response and policy (RADAAR)
This initiative improves regional data sharing and analysis for use in AMR planning, policy, and advocacy. The project laid the groundwork to strengthen the capacities of low- and middle-income countries to translate AMR knowledge – from data and evidence to effective policies. In 2024, RADAAR initiated the Evidence-Informed Policy Network with the World Health Organization in Bhutan, hosted a series of policy webinars, initiated online training modules, and conducted a systematic literature review on the economic evaluations of AMR.
Countries: Bangladesh, Bhutan, Cambodia, Cameroon, Eswatini, Ghana, Indonesia, Kenya, Laos, Malawi, Nepal, Nigeria, Pakistan, Papua New Guinea, Senegal, Sierra Leone, Tanzania, Timor-Leste, Uganda, Viet Nam, Zambia, Zimbabwe